Gold nanoparticles as an HIV entry inhibitor

Area of Science:

• Nanotechnology
• Virology
• Biochemistry

Background:

• Human Immunodeficiency Virus type 1 (HIV-1) remains a global health challenge.
• Antiviral therapies are crucial for managing HIV-1 infection.
• Gold nanoparticles (AuNPs) are being explored for various biomedical applications.

Purpose of the Study:

• To investigate the antiviral activity of polyethylene glycol-stabilized gold nanoparticles against HIV-1.
• To determine the cytotoxicity and efficacy of gold nanoparticles as an inhibitor of HIV-1.
• To elucidate the mechanism of gold nanoparticle-mediated inhibition of HIV-1.

Main Methods:

• Cytotoxicity assessment using the HeLa-CD4-LTR-B-gal cell line and luminescent assay.
• Determination of the 50% cytotoxicity concentration (IC50) for gold nanoparticles.
• Evaluation of gold nanoparticle inhibition against various HIV-1 isolates (M-tropic, T-tropic, dual tropic, resistant).

Main Results:

• The 50% cytotoxicity concentration (IC50) of gold nanoparticles was determined to be 1.12±0.05 mg/ml.
• Gold nanoparticles demonstrated inhibitory effects against multiple HIV-1 isolates, with inhibition concentrations ranging from 0.05 to 0.12 mg/ml.
• Experimental results indicated that gold nanoparticles inhibit HIV-1 entry by binding to the viral envelope glycoprotein gp120, thereby preventing attachment to CD4 receptors.

Conclusions:

• Polyethylene glycol-stabilized gold nanoparticles exhibit significant antiviral activity against HIV-1.
• Gold nanoparticles effectively inhibit HIV-1 replication by interfering with viral entry.
• These findings suggest that gold nanoparticles hold potential as novel antiviral inhibitors for HIV-1 therapy.